CAMBRIDGE, Mass., Jan. 7, 2015 /PRNewswire/ --www.onkaido.com/" target"_blank" rel"nofollow">Onkaido Therapeutics, a venture company formed, funded and wholly-owned by Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics, announced today that
